Display options
Cite
Li H, Wang Y, Li YZ. MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47. Tumour Biol. 2016;doi: 10.1007/s13277-016-5451-x.
Li, H., Wang, Y., & Li, Y. Z. (2016). MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, . https://doi.org/10.1007/s13277-016-5451-x
Li, Hui, et al. "MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47." Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine vol. (2016). doi: https://doi.org/10.1007/s13277-016-5451-x
Li H, Wang Y, Li YZ. MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47. Tumour Biol. 2016 Oct 11; doi: 10.1007/s13277-016-5451-x. Epub 2016 Oct 11. PMID: 27730543.
Copy Download .nbib Format: NLM
Share it on

Tumour Biol. 2016 Oct 11; doi: 10.1007/s13277-016-5451-x. Epub 2016 Oct 11.

MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Hui Li, Yan Wang, Yan-Zhong Li

Affiliations

  1. Department of Ophthalmology and Otorhinolaryngology, 456 Hospital of PLA, Ji'nan, 250031, People's Republic of China.
  2. Department of Otorhinolaryngology, Qilu Hospital of Shandong University, No. 107, West Wenhua Road, Lixia District, Ji'nan, 250012, Shandong, People's Republic of China.
  3. Department of Otorhinolaryngology, Key Laboratory of Otolaryngology of Health Ministry, No. 107, West Wenhua Road, Lixia District, Ji'nan, 250012, Shandong, People's Republic of China.
  4. Department of Otorhinolaryngology, Qilu Hospital of Shandong University, No. 107, West Wenhua Road, Lixia District, Ji'nan, 250012, Shandong, People's Republic of China. [email protected].
  5. Department of Otorhinolaryngology, Key Laboratory of Otolaryngology of Health Ministry, No. 107, West Wenhua Road, Lixia District, Ji'nan, 250012, Shandong, People's Republic of China. [email protected].

PMID: 27730543 DOI: 10.1007/s13277-016-5451-x

Abstract

The study aims to investigate the possible mechanisms of microRNA-133a (miR-133a) targeting CD47 on cell proliferation, apoptosis, migration, and invasion in laryngeal carcinoma. Forty-two laryngeal carcinoma tissue specimens confirmed by pathological examination from laryngeal carcinoma patients as the case group were collected, and 20 chronic laryngitis tissues were gathered as the control group. The human laryngeal carcinoma cell line Hep-2 was marked as the miR-133a mimic, negative control (NC), miR-133a inhibitor, CD47-siRNA, miR-133a inhibitor + CD47-siRNA, and Mock groups. The expression of CD47 protein and miR-133a was detected by immunohistochemistry (IHC) and qRT-PCR. Dual luciferase assay system was used to determine the relationship between CD47 and miR-133a. Western blotting was used to measure the protein expression of CD47 and miR-133a. 5-Ethynyl-2'-deoxyuridine (EDU) method was used to detect the cell proliferation, and flow cytometry and Transwell were used to measure the cell apoptosis and migration and invasion, respectively. The miR-133a expression in laryngeal carcinoma tissues was significantly lower, while the CD47 expression was higher than that in chronic laryngitis tissues (both P < 0.01). The expression of miR-133a in the miR-133a mimic group was significantly higher than that in other groups (P < 0.05), and the messenger RNA (mRNA) and protein expression of CD47 in the CD47-siRNA and miR-133a mimic groups were significantly lower than those in the Mock and NC group (all P < 0.05), while the mRNA and protein expression of CD47 in the miR-133a inhibitor group were higher than in other groups (all P < 0.05). After transfection, the CD47-siRNA group had the strongest inhibitory activity, while the number of living cells in the miR-133a inhibitor group was significantly higher than that in other groups (all P < 0.05). The apoptosis rates in the miR-133a mimic and CD47-siRNA groups were significantly higher than that in the Mock and NC groups (all P < 0.05). The cell numbers that penetrated membrane in the miR-133a mimic and CD47-siRNA groups were less than in the Mock and NC groups (all P < 0.05). Upregulated miR-133a could inhibit proliferation, invasion, and migration and promote cell apoptosis in laryngeal carcinoma by targeting CD47. miR-133a targeting CD47 could be a new direction in the diagnosis and treatment of laryngeal carcinoma.

Keywords: Apoptosis; CD47; Invasion; Laryngeal carcinoma; MicroRNA-133a; Migration; Proliferation

References

  1. Natl Med J India. 2014 Jan-Feb;27(1):56 - PubMed
  2. Clin Radiol. 2012 Feb;67(2):140-7 - PubMed
  3. Cell. 2009 Jul 23;138(2):271-85 - PubMed
  4. Expert Opin Ther Targets. 2013 Jan;17(1):89-103 - PubMed
  5. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7 - PubMed
  6. Crit Rev Biochem Mol Biol. 2015;50(3):212-30 - PubMed
  7. Br J Cancer. 2011 Mar 1;104(5):808-18 - PubMed
  8. Cell. 2005 Jan 14;120(1):15-20 - PubMed
  9. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Jun;24(12):535-8 - PubMed
  10. FEBS Lett. 2012 Mar 23;586(6):804-9 - PubMed
  11. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  12. Cancer. 1993 Nov 15;72(10):2979-85 - PubMed
  13. Curr Drug Targets. 2014;15(9):817-28 - PubMed
  14. Oncol Rep. 2012 Jun;27(6):1967-75 - PubMed
  15. Transfus Clin Biol. 2006 Mar-Apr;13(1-2):39-43 - PubMed
  16. Cell. 2009 Jul 23;138(2):286-99 - PubMed
  17. Int J Oncol. 2011 Nov;39(5):1099-107 - PubMed
  18. Mol Med Rep. 2014 Apr;9(4):1293-8 - PubMed
  19. Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2196-202 - PubMed
  20. Clin Cancer Res. 2008 May 1;14(9):2588-92 - PubMed
  21. Int J Cancer. 2010 Dec 15;127(12):2804-14 - PubMed
  22. Oncol Rep. 2012 Aug;28(2):465-72 - PubMed
  23. Int J Oncol. 2011 Jan;38(1):209-17 - PubMed
  24. Biochem Biophys Res Commun. 2012 Feb 10;418(2):378-83 - PubMed
  25. Br J Cancer. 2010 Mar 2;102(5):883-91 - PubMed
  26. Urol Oncol. 2013 Jan;31(1):115-23 - PubMed
  27. Eur Arch Otorhinolaryngol. 2010 Jul;267(7):1095-101 - PubMed
  28. Eur Arch Otorhinolaryngol. 2011 May;268(5):727-31 - PubMed
  29. J Laryngol Otol. 2010 Sep;124(9):990-4 - PubMed
  30. Autoimmun Rev. 2012 Mar;11(5):305-14 - PubMed
  31. Cell Death Dis. 2013 Nov 28;4:e934 - PubMed
  32. Oral Oncol. 2005 Nov;41(10):956-65 - PubMed
  33. Comp Funct Genomics. 2009;:837514 - PubMed
  34. J Exp Clin Cancer Res. 2011 Aug 08;30:73 - PubMed
  35. Turk J Med Sci. 2014;44(3):411-6 - PubMed
  36. Nat Rev Gastroenterol Hepatol. 2013 Feb;10(2):109-18 - PubMed
  37. FEBS Lett. 2011 Oct 20;585(20):3263-9 - PubMed
  38. Eur J Cancer. 2013 Dec;49(18):3924-35 - PubMed

Publication Types